If you’re taking Strattera, you may wonder whether you need to avoid or limit certain foods. Strattera doesn’t interact with any foods, but taking it with certain foods may affect how well your body ...

It generally takes 4 to 8 weeks to see a change in ADHD symptoms with Strattera. Some people see changes earlier, but the response is typically gradual and builds over time. Strattera (atomoxetine) is ...

Based in Tampa, Florida, Virginia Pelley is a former women's magazine editor who has written health and fitness content for Men's Journal, Cosmopolitan magazine, the Chicago Tribune, ...

Strattera (atomoxetine) is a nonstimulant ADHD medication. Strattera is not a controlled substance, but it can have other serious side effects, such as mental health issues. Strattera is a brand-name ...

Strattera vs. Ritalin: What Is the Difference? Strattera and Ritalin are medicines that children and adults can take to manage symptoms of attention deficit hyperactivity disorder (ADHD). Both drugs ...

Strattera (atomoxetine) is a prescription drug that’s used to treat attention deficit hyperactivity disorder (ADHD). Strattera comes as an oral capsule. Strattera is used in adults and certain ...

Strattera is a non-stimulant medication for ADHD that works by increasing norepinephrine in your brain. Common side effects of Strattera include dry mouth, nausea, and reduced appetite. Stimulants ...

The Food and Drug Administration (FDA) is advising health care professionals about a new warning for Strattera, a drug approved for attention deficit hyperactivity disorder (ADHD) in adults and ...

Eli Lilly could be facing generic competition far sooner than expected for Strattera, after a US court ruled that a key patent on the attention deficit hyperactivity disorder treatment is invalid. Eli ...

The Food and Drug Administration warned doctors Thursday about reports of suicidal thinking in some children and adolescents who are taking Strattera, a drug used to treat attention deficit ...

Eli Lilly’s big-earning ADHD med Strattera has succumbed to generics. Four drugmakers won FDA green lights for their copycats Tuesday, and the competitive pressure is expected to quickly tank the ...